Tropical medicine & international health : TM & IH 2017 10 27() doi 10.1111/tmi.12994
To estimate the Brazilian direct and indirect costs of human visceral leishmaniasis (VL) in 2014.
Cost-of-illness study on the Brazilian public health system and societal perspective. VL cases registered in the Notifiable Diseases Information System in the year of 2014 were considered. Direct medical costs regarding diagnostic, treatment, and care provided to VL patients were estimated through the top-down approach. The indirect costs related to productivity loss due to premature mortality and morbidity were estimated by means of the human capital method.
In 2014, 9,895 suspected cases of VL were reported in the Notifiable Diseases Information System, and 3,453 were later confirmed. There were 234 patients with Leishmania-HIV coinfection underwent a secondary prophylaxis. The total cost of VL in Brazil was US$ 14,190,701.50 (US$ 14,189,150.10 to 14,199,940.53), that varied according to the sensitivity analysis. The total of direct medical costs corresponded to US$ 1,873,681.96 (US$1,872,130.55 to 1,882,920.99), and the majority of costs was associated with hospitalization (40%), followed by treatment (22%), and secondary prophylaxis (18%). Productivity loss corresponded to US$ 11,421,683.37 for premature mortality and US$ 895,336,18 for work absence due to hospitalization by the illness.
VL represents an expensive health problem for the Brazilian public health system and society, mainly because of its productivity loss due to premature mortality. Interventions to reduce of VL lethality could have a great impact on decreasing the cost of illness. This article is protected by copyright. All rights reserved.